Abstract |
Respiratory syncytial virus ( RSV) infection is the leading cause of hospitalisation for children under 5 years of age and causes excess mortality in the elderly. There is still no approved vaccine available, although the disease can be curtailed by RSV-specific monoclonal antibody. The only antiviral drug approved for the treatment of RSV infection is ribavirin aerosol, but this treatment is cumbersome and its efficacy is questionable. A new antiviral, GS-5806, which interferes with virus-cell fusion, has proven efficacious in experimental RSV infections in adults.
|
Authors | Erik De Clercq |
Journal | International journal of antimicrobial agents
(Int J Antimicrob Agents)
Vol. 45
Issue 3
Pg. 234-7
(Mar 2015)
ISSN: 1872-7913 [Electronic] Netherlands |
PMID | 25684638
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
Chemical References |
- Antiviral Agents
- Indazoles
- Pyrazoles
- Sulfonamides
- Ribavirin
- presatovir
|
Topics |
- Administration, Inhalation
- Antiviral Agents
(therapeutic use)
- Humans
- Indazoles
- Pyrazoles
(therapeutic use)
- Respiratory Syncytial Virus Infections
(drug therapy)
- Ribavirin
(therapeutic use)
- Sulfonamides
(therapeutic use)
- Treatment Outcome
|